(FRANKFURT) - The German pharmaceutical and chemical group Merck posted Wednesday strong second quarter results despite negative foreign exchange effects, it said in a statement.

Net profit more than doubled to 207.4 million euros (327 million dollars), a leap of 142.6 percent from the same period a year earlier, in part the result of the group's sale of its generic drug activities.

Sales gained 6.1 percent to 1.9 billion euros, the statement said.

Analysts polled by Dow Jones Newswires had forecast an average net profit of 215 million euros.

Operating profit climbed by 15.5 percent to 320.5 million euros, below the analysts' average outlook of 327 million.

Merck reiterated its 2008 targets, including sales growth of between five to nine percent.

The group said the euro's rise against other major currencies had hurt its results.

But pharmaceutical sales nonetheless reached 1.2 billion euros, owing in part to Merck's cancer drug Erbitux, sales of which jumped by 24 percent to 145 million euros.

The scope of Merck's activities were marked by two major changes last year, the sale of its generic drug activities and the purchase of the Swiss group Serono.

Text and Picture Copyright 2008 AFP. All other Copyright 2008 EUbusiness Ltd. All rights reserved. This material is intended solely for personal use. Any other reproduction, publication or redistribution of this material without the written agreement of the copyright owner is strictly forbidden and any breach of copyright will be considered actionable.